STOCKHOLM, Jan. 28, 2025 /PRNewswire/ -- EQT is pleased to announce that EQT Life Sciences has led a USD 75 million Series B funding round in Atalanta Therapeutics ("Atalanta" or "the Company").

Atalanta Therapeutics Closes Oversubscribed $97 Million Series B Financing to Advance Two RNAi Therapies for CNS Diseases to Clinical Trials ...

A recent study published in Cell reveals that the repeated DNA sequence that leads to Huntington’s disease (HD) expands ...

People genetically susceptible to Huntington's disease often see their movement, mood, and cognition decline slowly over time.

Researchers have made a major breakthrough in our understanding of Huntington's disease. This genetic disorder has long been ...

Scientists are unraveling the mystery of what triggers Huntington's disease, a devastating and fatal hereditary disorder that ...

Subtle changes in the brain, detectable through advanced imaging, blood and spinal fluid analysis, happen approximately twenty years before a clinical motor diagnosis in people with Huntington's ...

An eastern German region said Friday it is lifting a ban on the transport of animals that was imposed last weekend after foot ...

CAMBRIDGE, Massachusetts ‒ For decades it's been one of the defining mysteries of Huntington's disease. Why does the terrible ...

This microscope photo provided by the McLean Hospital's Harvard Brain Tissue Resource Center in January 2024 shows cells in the caudate nucleus structure of the brain in a person with Huntington's ...

Scientists are unraveling the mystery of what triggers Huntington’s disease, a devastating and fatal hereditary disorder that strikes in the prime of life, causing nerve cells in parts of the ...